Abstract
SUMMARY: The reduced tumor suppression activity of hypomorphic variants of the TP53 gene was used by Indeglia and colleagues to corroborate PADI4 as a p53 target. The study makes a noteworthy advancement in comprehending the downstream implications of TP53-PDI4, including potential predictions of survival and the efficacy of immunotherapy. See related article by Indeglia et al., p. 1696 (4).
Original language | English |
---|---|
Pages (from-to) | 1518-1520 |
Number of pages | 3 |
Journal | Cancer Discovery |
Volume | 13 |
Issue number | 7 |
DOIs | |
State | Published - 7 Jul 2023 |
ASJC Scopus subject areas
- Oncology